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 Invasive breast cancer is the most common malignancy in women. At present, in the majority of cases it is recognized at 
an early stage. Its most common site of metastasis is the axilla region, and for women without clinically suspected lymph 
nodes a sentinel lymph node biopsy (SLNB) is the method of choice in diagnostics and treatment process. It allows, in 
many cases, axillary lymphadenectomy to be avoided and the risk of complications after a surgical treatment to be dimi-
nished. Extracapsular extension (ECE) of nodal metastasis, defined as extension of cancer cells through the nodal capsule, 
is an important prognostic factor. The aim of this paper is to review the literature on ECE in the sentinel lymph node (SLN).
Key words: breast cancer, sentinel lymph node, extracapsular extension
How to cite:
Kędzierawski P. Breast cancer – extracapsular extension in the sentinel lymph node. NOWOTWORY J Oncol 2020; 70: 203–205. 
Introduction
For the last decade, axillary lymphadenectomy (ALND) has 
not been mandatory for patients with 1-2 sentinel nodes with 
macrometastases who were undergoing lumpectomy and 
adjuvant radiotherapy as part of their treatment, according to 
an ACOSOG Z0011 trial or an AMAROS trial. The outcomes of 
these trials showed no differences in recurrence and survival 
between patients who had undergone ALND and those who 
had not undergone ALND, but the presence or absence of 
extracapsular extension was not analyzed in these trials [1–3].
ECE can be connected with poor prognosis and its diame-
ter should be determined, because in many cases this factor 
determines the necessity of performing an ALND or regional 
lymph node radiotherapy.
Biological subtype of breast cancer and positive 
SLN
Luminal tumours are the most common breast cancer and 
they represent about 70% of all cases of breast cancer [4–7]. In 
most patients with Luminal A cancer, surgery is used up-front. 
In women with clinically negative lymph nodes, SLNB is the 
method of choice instead of an ALND. Some authors point 
to different factors influencing the presence of metastases in 
the sentinel lymph nodes, such as: age, the diameter of the 
tumour, grade, and the lobular type of the cancer. Luminal A 
breast cancers are usually of low histological grade with slow 
growth and a good prognosis, however quite frequently, the 
illness is more advanced at the moment of diagnosis [8–9]. For 
women with Luminal B HER2 negative cancer, an additionally 
high Ki-67 factor is connected with the possibility of a positive 
sentinel lymph node [10–11].
For triple negative or HER2 positive cancer patients, the 
strategy of treatment has changed lately and therapy usually 
starts with chemotherapy [12]. For patients with an overexpres-
sion of the HER2 receptor, the probability of metastasis to SLN 
and ECE is much higher [11]. Systemic treatment leads, in more 
than 40% of patients, to a complete pathological response 
(ypT0N0) and very often SLNB is advised. However, for women 
with clinically suspected or with metastasis diagnosed before 
treatment an ALND is mandatory. On the other hand, for triple 
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negative or HER2 positive T1 patients, with tumours less than 
1cm in diameter, surgery is an up-front strategy [12–16]. 
ECE in a sentinel lymph node and correlation 
with non-sentinel lymph node (NSLN) 
metastases
In most of the papers presented, ECE in sentinel lymph nodes 
is connected with metastases to NSLNs. More metastatic SLNs 
are connected with a higher probability of positive NSLNs. The 
ratio between metastatic sentinel lymph nodes and removed 
sentinel lymph nodes is very important. The higher the ratio, 
the greater the probability of metastases to NSLNs [17–21]. In 
his paper, Palamba showed that for patients with ECE the pro-
bability of the occupation of additional lymph nodes by cancer 
cells is much higher – 84.6% for massive, 58.5% for minimal, 
and only 14.5% for sentinel lymph nodes without extracap-
sular extension [22]. Similar conclusions were presented by 
Gooch et al. The risk of metastases to NSLNs was connected 
with the diameter of ECE. For infiltration greater than 2 mm, 
or for lesser than 2 mm, or for no extracapsular infiltration, 
the probability of the occupation of more than four axillary 
lymph nodes was 33%, 8.5% and 2.5%, respectively [10]. In 
yet another paper, this feature was also presented, but it was 
not an independent factor for disease free survival (DFS) and 
overall survival (OS) [23]. Schwentner, analyzing the outcomes 
of 324 women showed that the probability of increasing pN 
status (pN1 to pN2-3) was much higher in patients with ECE 
after performing an axillary dissection [24].
The diameter of ECE in the sentinel lymph node
In the literature, we do not meet a correct definition of extra-
capsular extension in connection with its clinical meaning. In 
pathological reports, however, very often, we find only the 
sentence that ECE is present and in some that ECE is absent 
which can be understood as the true absence of ECE or as the 
situation that this feature was not assessed by the pathologist. 
In the analysis presented by Vane et al., in a group of 3502 
patients, information on ECE was available for about 60% 
of them [10]. Nottegar et al. have performed an analysis of 
proper papers concerning the issue of ECE, and five articles 
were included by them in their meta-analysis. In four out of 
the five articles, the analysis was connected only with a short 
piece of information that ECE was present or absent without 
estimation of its diameter [25]. The lack of information on the 
diameter of the ECE can be accepted in a situation where an 
axillary dissection was performed and there is a huge number 
of metastatic lymph nodes, which is connected with poorer 
prognosis and the necessity of systemic treatment, not only for 
cancers with worse prognosis (triple negative or non-luminal) 
but also for patients with luminal ones. After SLNB and the 
presence of ECE, it is mandatory to estimate the diameter of 
the ECE, because not only is it connected with prognosis, but 
it also influences the planning of further therapy. The relevance 
for prognosis of extracapsular extension was proven in patients 
with other cancers [26–28]. 
In the 5th edition of The American Joint Committee of 
Cancer (AJCC) Cancer Staging Manual, the presence of ECE 
was recognised and named as subcategory pN1biii, but was 
removed from following editions [29]. This factor has also not 
been assessed in clinical trials. In the ACOSOG Z0011 trial, 
patients with ECE were excluded from the analysis and in the 
AMAROS trial this factor has not been evaluated. The authors 
pointed to the fact that the diameter of the ECE can influence 
both DFS and OS. When this diameter exceeded 2 mm, the risk 
of locoregional failure was greater than 20% and influenced 
DFS [30–32]. Nevertheless, this fact was not confirmed by 
others. In their paper Choi et al. presented the fact that in cases 
of ECE less than 2 mm the risk of recurrence was the same as 
for patients without ECE [33]. 
Similar conclusions were shown by Barrio et al. However, 
the mean time of observation was only 21 months, there were 
no nodal failures in patients with ECE in sentinel lymph nodes 
and they were not treated with an axillary dissection, but rather 
biologically oriented systemic treatment and locoregional 
radiotherapy were used. The risk of nodal failure in this group 
was only 1.5% [34]. The research of Kanyilmaz et al. has shown 
that the extent of the ECE is a prognostic factor for survival in 
pT1-2N1 breast cancer patients with a diameter of extracapsu-
lar extension greater than 1mm. This factor, according to the 
authors, was connected with shorter OS and DFS [35].
Conclusions
In an era of diminishing surgical treatment in the breast area 
and axilla region, it seems to be very important to precisely 
estimate the diameter of any extracapsular extension in the 
sentinel lymph nodes. In an era of biologically directed syste-
mic treatment and conformal radiotherapy, it is probable that 
we can avoid the harmful consequences of surgical procedures 
in many patients [12].
Pathologists should include the diameter of the ECE in their 
reports to help, much more so than presently, clinicians take 
decisions about the best oncological treatment for women 
with breast cancer. As the data mentioned shows, a diameter 
of 1–2 mm for an extracapsular extension in SLN is crucial (pivo-
tal). The prognostic importance of ECE must also be confirmed 
by future clinical trials.
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